With more and more people being affected by the effects of its COVID vaccine, and many falling dead after receiving recommended doses, Pfizer wastes no time recruiting a segment of the population that until now remained untouchable, but that has potentially a great chance to produce huge profits for the American pharmaceutical giant.
As the covid vaccination campaign progresses around the world, Pfizer wants to go one step further and see if it can administer its experimental vaccine to minors as well.
The American pharmaceutical company announced that it has started a clinical trial with children aged between 6 months to 11 years.
These kinds of tests, Pfizer says, are a crucial step in later obtaining permission from regulatory agencies to vaccinate minors and control the spread of the pandemic.
For now, the first volunteer participants in the trial have already received the initial injection developed by Pfizer and Germany’s BioNTech.
Pfizer, thus joining Moderna in testing the vaccine in minors, intends in this initial phase of the clinical trial to have 144 children, with which it wants to identify the best dose for three age groups: between 6 months and 2 years, between 2 and 5 years and between 5 and 11 years.
It goes without saying studies like this with such an insignificant sample of children are insufficient to verify the effectiveness and safety of a vaccine. In general, these types of experiments are done to better control the negative results that the vaccine may have in small and unrepresentative populations, while what is determined as good results can be inflated.
Children will begin receiving a 10-microgram dose of the serum to progressively increase it, according to Pfizer, although participants also have the option of choosing the 3-microgram dose, compared to the two 30-microgram doses that adults receive.
In the next phase, researchers say they will analyze the effectiveness and safety of the selected doses, in which some participants will receive the vaccine and others a placebo.
“Pfizer is highly experienced in conducting clinical trials of vaccines in children and infants and is committed to improving the health and well-being of children in these trials, which are thoughtfully designed,” the company explained in a statement.
According to “experts,” inoculating children, who make up about 20% of the US population, is essential to ending the coronavirus pandemic, noting that the country is unlikely to achieve immunity until minors are also vaccinated.
This statement is absolutely false, as observations made with much larger populations of children have shown that children not only do not get sick but also do not transmit COVID. For this reason, injecting them with an experimental vaccine is not only risky but unnecessary. It would be like taking a laxative without having digestive problems.
Moderna already announced that it had started its clinical trials in children under 12 years old on March 16, something that began for adolescents between 12 and 17 years old last December.
In addition, according to the New York Times, Johnson & Johnson plans to test its single-dose vaccine in infants and newborn babies after testing it in older children.
Pfizer’s announcement comes two days after the pharmaceutical company claimed to have started the first phases of a clinical trial of an oral drug that could be used after the first symptoms of COVID infection.
As you can see, this is an experimental race to earn a lot of money, not a rigorous scientific process to determine the safety and effectiveness of vaccines. In fact, drug companies have not even been able to test the effectiveness of their adult vaccines.
What has been confirmed is that Pfizer’s vaccine causes thrombosis in many of the people who have been injected with its product, and neither Pfizer nor health authorities can explain how a patient without circulatory problems mysteriously dies after receiving the first or second dose.
We will not really know if Pfizer develops a safe and effective vaccine. What we do know is that the pharmaceutical giant will be able to modify children’s RNA material as it happens with adults and the consequences that such genetic manipulation will have are unknown to the public.